Prothena reburies drug after 2nd swing at rare disease misses, plans 'substantial' layoffs
Prothena has buried birtamimab for the second time. A phase 3 trial of the anti-amyloid antibody in the rare disease AL amyloidosis missed its primary endpoint, prompting the biotech to end development and plan a “substantial reduction in organizational size.”
Prothena has buried birtamimab for the second time. A phase 3 trial of the anti-amyloid antibody in the rare disease AL amyloidosis missed its primary endpoint, prompting the biotech to end development and plan a “substantial reduction in organizational size.”
